SCHEMBL4907487

SCHEMBL4907487

N#Cc1c(C(F)(F)F)cc(-c2ccc(O)c(Cl)c2)n(Cc2ccc(F)cc2F)c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.66
NR1H2 P55055 3/20 0.66
NR1H3 Q13133 3/20 0.66
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 5/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 2/20 0.38
HTT P42858 2/20 0.38
AR P10275 2/20 0.36
MAPK14 Q16539 3/20 0.36
CYP19A1 P11511 3/20 0.36
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
POLB P06746 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2386436 0.91 RXRA (0.67) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL4899639 0.87 RXRA (0.74) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2391082 0.85 RXRA (0.73) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2389916 0.84 RXRA (0.63) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL14944181 0.84 NR1H2 (0.47) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL14214400 0.83 RXRA (0.84) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2262731 0.83 RXRA (0.83) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2389784 0.83 RXRA (0.70) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2389286 0.82 RXRA (0.84) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL2388573 0.82 RXRA (0.67) RXRANR1H2NR1H3ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 RXRA 20/4885NR1H2 1/4885NR1H3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.